

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
OFFICE OF THE SENATE
PUBLIC RECORDS

01 FEB 14 PM 2:03

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Bennett, Turner & Coleman, LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1900 K Street NW, Suite 750 Washington, DC 20006			
3. Principal Place of Business (if different from line 2) City: State/Zip (or Country)			
4. Contact Name Albert Cacoza		Telephone 202-833-4500	E-mail (optional) 5. Senate ID #
7. Client Name <input type="checkbox"/> Self AstraZeneca LP		6. House ID #	

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ Termination Date _____ 11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input checked="" type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	

Signature _____

Printed Name and Title Terry S. Coleman, Partner

LD-2 (REV. 6/98)

PAGE 1 of 2

Registrant Name Bennett, Turner & Coleman, LLP Client Name AstraZeneca LP

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer drugs

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Sam Turner, Partner		<input type="checkbox"/>
Elizabeth Goss, Partner		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

To the degree that public policies, either laws or regulations, commercially benefit AstraZeneca LP, so too AstraZeneca PLC will benefit. AstraZeneca PLC is the parent company of AstraZeneca LP and the parent benefits in the commercial success of its subsidiary.

Signature Terry Coleman Date February 13, 2001

Printed Name and Title Terry S. Coleman, Partner